Dapagliflozin, sold under the brand names Farxiga and Forxiga among others, is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. it also can induce weight loss

1. Sharing – Discussion
Dapagliflozin and Weight Loss
Medical Department – HETERO Indonesia

2. 1. DAPAZOX  berapa mg ?
2. Ada / tidak dikombinasi dengan OAD lainnya?
3. Penurunan BB 3-6 kg dalam waktu berapa lama ….
4. Pasien obesitas / tidak ….

4. Algoritma Pengelolaan DM Tipe 2
Sasaran kendali glukosa darah  HbA1c <7% (individualisasi)

5. https://www.pharmacistopinions.com/dapagliflozin-mechanism-of-action/
slight weight reduction during gliflozin therapy  losing calories (or glucose)
by the glucosuria effect  it may be beneficial for obese patients.

8. Emerging Role of SGLT-2 Inhibitors for
the Treatment of Obesity
Drugs (2019) 79:219–230
https://doi.org/10.1007/s40265-019-1057-0
SGLT2 inhibitors (e.g., dapagliflozin,
canagliflozin, and empagliflozin) and glucagon-like
peptide-1 receptor agonists (GLP1-RAs; e.g.,
exenatide, liraglutide, and semaglutide) are both
used for T2D treatment, but they also lead to
bodyweight loss, largely accounted for by
body fat reduction.
The magnitude of weight loss is modest both in T2D
and in obesity without diabetes.
For approved SGLT2 inhibitors  on average some
1.5–2 kg weight loss (placebo-adjusted), for GLP1-
RAs  2–4 kg, and for the combination  3–5 kg.

9. WEIGHT LOSS EFFECT OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2)
INHIBITORS IN PATIENTS WITH OBESITY WITHOUT DIABETES : A SYSTEMATIC
REVIEW
Acta Endocrinologica (Buc), vol. XVIII, no. 2, p. 216-224, 2022

10. Dapagliflozin Reduces Fat Mass without
Affecting Muscle Mass in Type 2 Diabetes
J Atheroscler Thromb, 2018; 25: 467-476.
http://doi.org/10.5551/jat.40873

11. Dapagliflozin treatment for six
months significantly decreased
body weight, total fat mass, and
body fat percentage.
Changes in body fat percentage were
significantly correlated with changes in
body weight

12. Conclusion
Treatment with dapagliflozin for six months significantly improved glycemic
control and reduced body weight without reducing total or skeletal
muscle mass in T2DM patients.
Regarding the balance between fat and muscle mass, dapagliflozin is
promising as a new agent for the treatment of T2DM.